Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, has announced a $10 million public offering. The offering includes 20 million shares of common stock (or equivalents) at $0.50 per share, along with Series C and D warrants to purchase up to 20 million additional shares each.
The Series C warrants have a 5-year expiration while Series D warrants expire in 12 months, both with an exercise price of $0.50 per share. The offering is expected to close around June 27, 2025. Proceeds will fund R&D activities and general corporate purposes, with A.G.P./Alliance Global Partners acting as sole placement agent.
Reviva Pharmaceuticals (NASDAQ: RVPH), un'azienda farmaceutica in fase avanzata specializzata in malattie del sistema nervoso centrale, infiammatorie e cardiometaboliche, ha annunciato un'offerta pubblica da 10 milioni di dollari. L'offerta comprende 20 milioni di azioni ordinarie (o equivalenti) a 0,50 dollari per azione, insieme a warrant Serie C e D per l'acquisto di ulteriori 20 milioni di azioni ciascuno.
I warrant Serie C hanno una scadenza di 5 anni, mentre i warrant Serie D scadono in 12 mesi, entrambi con un prezzo di esercizio di 0,50 dollari per azione. La chiusura dell'offerta è prevista intorno al 27 giugno 2025. I proventi finanzieranno attività di R&S e scopi aziendali generali, con A.G.P./Alliance Global Partners come unico agente di collocamento.
Reviva Pharmaceuticals (NASDAQ: RVPH), una compañía farmacéutica en etapa avanzada enfocada en enfermedades del sistema nervioso central, inflamatorias y cardiometabólicas, ha anunciado una oferta pública de 10 millones de dólares. La oferta incluye 20 millones de acciones ordinarias (o equivalentes) a 0,50 dólares por acción, junto con warrants Serie C y D para comprar hasta 20 millones de acciones adicionales cada uno.
Los warrants Serie C tienen una vigencia de 5 años, mientras que los warrants Serie D expiran en 12 meses, ambos con un precio de ejercicio de 0,50 dólares por acción. Se espera que la oferta cierre alrededor del 27 de junio de 2025. Los ingresos financiarán actividades de I+D y propósitos corporativos generales, con A.G.P./Alliance Global Partners como único agente colocador.
Reviva Pharmaceuticals (NASDAQ: RVPH)는 중추신경계, 염증 및 심장대사 질환에 중점을 둔 후기 단계 제약회사로, 1,000만 달러 규모의 공개 모집을 발표했습니다. 이번 모집에는 2,000만 주의 보통주(또는 이에 상응하는 주식)를 주당 0.50달러에 제공하며, 각각 최대 2,000만 주를 추가로 매수할 수 있는 시리즈 C 및 D 워런트가 포함됩니다.
시리즈 C 워런트는 5년 만기이며 시리즈 D 워런트는 12개월 만기로, 두 워런트 모두 행사가격은 주당 0.50달러입니다. 모집 마감은 2025년 6월 27일경으로 예상되며, 수익금은 연구개발 활동과 일반 법인 목적에 사용될 예정입니다. A.G.P./Alliance Global Partners가 단독 배정 대행사로 참여합니다.
Reviva Pharmaceuticals (NASDAQ : RVPH), une entreprise pharmaceutique en phase avancée spécialisée dans les maladies du système nerveux central, inflammatoires et cardiométaboliques, a annoncé une offre publique de 10 millions de dollars. L'offre comprend 20 millions d'actions ordinaires (ou équivalents) au prix de 0,50 dollar par action, ainsi que des bons de souscription des séries C et D permettant d'acheter jusqu'à 20 millions d'actions supplémentaires chacun.
Les bons de souscription de la série C ont une durée de 5 ans, tandis que ceux de la série D expirent dans 12 mois, tous deux avec un prix d'exercice de 0,50 dollar par action. La clôture de l'offre est prévue aux alentours du 27 juin 2025. Les fonds serviront à financer les activités de R&D et les besoins généraux de l'entreprise, avec A.G.P./Alliance Global Partners agissant en tant qu'agent unique de placement.
Reviva Pharmaceuticals (NASDAQ: RVPH), ein Pharmaunternehmen in der Spätphase, das sich auf ZNS-, entzündliche und kardiometabolische Erkrankungen spezialisiert hat, hat eine öffentliche Platzierung in Höhe von 10 Millionen US-Dollar angekündigt. Das Angebot umfasst 20 Millionen Stammaktien (oder Äquivalente) zu 0,50 US-Dollar pro Aktie sowie Serie-C- und D-Warrants zum Kauf von jeweils bis zu 20 Millionen zusätzlichen Aktien.
Die Serie-C-Warrants haben eine 5-jährige Laufzeit, während die Serie-D-Warrants in 12 Monaten verfallen, beide mit einem Ausübungspreis von 0,50 US-Dollar pro Aktie. Der Abschluss des Angebots wird für etwa 27. Juni 2025 erwartet. Die Erlöse werden für F&E-Aktivitäten und allgemeine Unternehmenszwecke verwendet, wobei A.G.P./Alliance Global Partners als alleiniger Platzierungsagent fungiert.
- Secured $10 million in additional funding for R&D and operations
- Support from both existing and new healthcare-focused institutional investors
- Significant dilution with 20 million new shares at $0.50 per share
- Additional potential dilution from 40 million warrant shares
- Offering price of $0.50 suggests significant discount to market price
Insights
Reviva's $10M offering at $0.50/share represents significant dilution while providing essential capital for its late-stage pharmaceutical development.
Reviva Pharmaceuticals has priced a
This financing structure is particularly aggressive, as the total potential dilution could reach 60 million shares if all warrants are exercised - tripling the offering's initial share count. The
The company plans to use proceeds for research and development activities and general corporate purposes, which is critical for a late-stage pharmaceutical company developing CNS, inflammatory, and cardiometabolic therapies. However, investors should note this capital raise likely indicates Reviva needs this funding to sustain operations and advance its clinical pipeline.
This offering follows a shelf registration filed in February 2024, suggesting management anticipated needing additional capital this year. The participation of both existing and new healthcare-focused institutional investors provides some validation, though the pricing terms remain highly dilutive. The offering is expected to close around June 27, 2025.
CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with existing and new healthcare focused institutional investors for the purchase and sale of 20,000,000 shares of its common stock (or common stock equivalents in lieu thereof) together with Series C warrants to purchase up to 20,000,000 shares of common stock (the "Series C Warrants") and Series D warrants to purchase up to 20,000,000 shares of common stock (the "Series D Warrants"), at a combined offering price of
The Series C Warrants and the Series D Warrants will have an exercise price of
The closing of the offering is expected to occur on or about June 27, 2025, subject to the satisfaction of customary closing conditions. The Company currently intends to use the net proceeds from the offering to fund research and development activities and for working capital and other general corporate purposes.
A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
The securities are being offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-276848), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 2, 2024, and declared effective by the SEC on February 13, 2024. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and accompanying base prospectus, when available, may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with the satisfaction of customary closing conditions related to the offering and uncertainties related to the closing and use of net proceeds from the offering. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s final prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company’s Form 10-K for the year ended December 31, 2024 and Form 10-Q for the quarter ended March 31, 2025.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
REVIVA CONTACTS:
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
What is the size and price of Reviva Pharmaceuticals (RVPH) June 2025 public offering?
How many warrants are included in RVPH's June 2025 offering?
What will Reviva Pharmaceuticals use the proceeds for?
When will RVPH's June 2025 public offering close?
Who is the placement agent for RVPH's June 2025 offering?
